
Dr Matthew Fyfe, Head of Chemistry and Intellectual Property at TopiVert, gives an illuminating look into the latest developments in …

The FDA has announced its decision to approve the use of Novartis’ combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in …

Johnson & Johnson has revealed new data on its new depression drug esketamine, its chemically ‘left-handed’ version of the controlled …

Genmab and Janssen have revealed that their combination of Darzalex (daratumumab) with bortezomib (Velcade), melphalan, and prednisone (VMP) has received …

AstraZeneca has confirmed it has signed a deal to jettison its schizophrenia drug Seroquel and its extended release version Seroquel …

After more than a month of uncertainty, Takeda has finally confirmed it has managed to successfully acquire Shire, agreeing on …

It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due …

The city of Los Angeles has levied legal action against a number of pharmaceutical firms for their role in advancing …

Mallinckrodt paid $80 million, with a further $345 million dependent on milestones, to acquire InfaCare in the hope that the …

It is timely to reflect on how we can best implement the revised GVP module (V) concerning risk management in …

Bristol-Myers Squibb has extended its existing collaboration with Flatiron Health by three years and expanded the efforts both will be …

Dr Daniel Bailey, Senior Lecturer in Health, Nutrition and Exercise at the University of Bedfordshire, discusses the benefits of the …

Research into dementia has waned in recent times as researchers struggle to pin down concrete advancements, leading to the withdrawal …

Promising new findings have been revealed in the efficacy of MDMA in treating post-traumatic stress disorder (PTSD).

In the pharma industry, we tend to use a lot of acronyms. Even in every day life, we are shortening …

In Novartis’ recently released Q1 results, which largely beat analysts’ estimates, Sandoz was a black spot on its record – …

An error in the automated system left 450,000 women without an invite for breast screening and Jeremy Hunt, the UK’s …

Bristol-Myers Squibb has terminated two pivotal Phase 3 trials of BMS-986205, an IDO1 inhibitor acquired through its $800 million acquisition …

Samsung BioLogics’ shares have been hit hard, after the South Korean company was handed a notice of suspected breach of …

Aaron Traywick, the 28-year-old CEO of biotech startup Ascendance Biomedical who made headlines when he injected himself with an untested …